News

POET Technologies Announces Delisting from TSXV While Staying on Nasdaq

POET Technologies Announces Delisting from TSXV While Staying on Nasdaq

POET Technologies Delisting from TSXV

POET Technologies Inc. (NASDAQ: POET) has made a significant announcement regarding its future in the stock market. The company has decided to proceed with a voluntary delisting of its common shares from the TSX Venture Exchange (TSXV). This decision marks a strategic shift aimed at streamlining its trading operations and enhancing shareholder value.

Company’s Transition to Nasdaq

Despite this delisting, POET Technologies will continue to maintain its listing on the Nasdaq Capital Market, where its shares are actively traded under the ticker symbol "POET". The company anticipates that as of the close of trading on an upcoming day, its shares will cease to be listed and traded on the TSXV. This change is expected to have no adverse impact on the company’s position on Nasdaq, which represents the majority of its trading volume.

Reasons for the Delisting

The management at POET believes that the delisting from the TSXV will provide a more centralized market for its shares. By focusing on Nasdaq, the company aims to improve liquidity and make trading its shares more straightforward for investors. This strategic move is designed to create an enhanced trading environment, promoting investor participation and potential boosts in shareholder value.

Ongoing Reporting and Compliance

Even after the delisting from the TSXV, POET will continue to operate as a reporting issuer under Canadian securities laws. This means that it will maintain its commitment to providing comprehensive disclosure and insights regarding its operations and performance, ensuring that shareholders remain well-informed.

Future for Shareholders

Shareholders of POET can continue trading their shares on Nasdaq through their brokers. For those who hold shares in Canadian brokerage accounts, it is advisable to consult with their brokers regarding the best practices for trading on the Nasdaq exchange. This accessibility is crucial for maintaining a satisfied shareholder base and ensuring that trading operations remain seamless.

About POET Technologies

POET Technologies is recognized for its innovative contributions to the high-speed optical communications sector. The company is focused on designing and developing products such as optical engines and light sources, primarily targeting the artificial intelligence systems market and hyperscale data centers. The cornerstone of POET’s technology is the POET Optical Interposer™, a patented platform that simplifies the integration of electronic and photonic devices into a single chip. This technology allows for efficient production, reduced costs, and energy consumption, which are vital in today's fast-paced tech landscape.

Headquartered in Toronto, Canada, POET Technologies operates globally with additional facilities in Allentown, PA, Shenzhen, China, and Singapore. The company’s commitment to revolutionizing the communication technology landscape is evident in its advancements, which also address critical challenges in 5G networks and autonomous vehicle systems.

Contact Information

For more information, you can reach out to the media relations contact:

Adrian Brijbassi
Email: Adrian.brijbassi@poet.tech

Thomas R. Mika, EVP & CFO
Email: tm@poet.tech

Frequently Asked Questions

Why is POET Technologies delisting from TSXV?

POET Technologies is delisting from TSXV to centralize its trading operations and focus on enhancing liquidity on Nasdaq, where it trades primarily.

Will POET still be listed on Nasdaq?

Yes, POET Technologies will continue to be listed on the Nasdaq Capital Market under the ticker symbol "POET".

What should shareholders do about trading post-delist?

Shareholders can trade their shares on Nasdaq through their brokers. Those with Canadian brokerage accounts should confirm trading methods for Nasdaq.

How does the delisting affect liquidity for the shares?

The company believes that delisting from TSXV will improve liquidity by concentrating trading activity on the Nasdaq exchange.

What products does POET Technologies offer?

POET Technologies offers high-speed optical modules, optical engines, and light source products primarily for data centers and AI systems.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles